📊 HYPR Key Takeaways
Is HYPR a Good Investment? Thesis Analysis
Hyperfine demonstrates viable product economics with 49.8% gross margins, but faces severe profitability challenges with -273.4% operating margin and only 5.2% revenue growth. Annual operating cash burn of $27.9M against $13.6M revenue creates an unsustainable trajectory, providing approximately 1.2 years of cash runway at current burn rates without revenue acceleration or further capital.
Why Buy HYPR? Key Strengths
- Strong gross margin of 49.8% indicates viable core product economics and unit-level profitability
- Fortress balance sheet with $35.1M cash, zero debt, and strong liquidity ratios (4.34x current ratio)
- Improving EPS trend (+23.2% YoY) suggests operational adjustments and cost management progress
HYPR Investment Risks to Consider
- Severe operating losses of -$37.1M with -273.4% operating margin indicate massive pre-profitability burn unsustainable without revenue acceleration
- Operating cash flow of -$27.9M annually against $13.6M revenue demonstrates negative unit economics at operating expense level
- Anemic 5.2% YoY revenue growth suggests weak market adoption and commercialization execution on core product
Key Metrics to Watch
- Revenue growth trajectory - requires acceleration to minimum 30-50% YoY to justify current operating expense structure
- Path to positive operating cash flow and timeline to break-even
- Cash burn rate and runway - critical inflection point if burn exceeds $28M annually or revenue fails to accelerate
HYPR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.34x current ratio provides a solid financial cushion.
HYPR Profitability Ratios
HYPR vs Healthcare Sector
How Hyperfine, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HYPR Overvalued or Undervalued?
Based on fundamental analysis, Hyperfine, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HYPR Balance Sheet & Liquidity
HYPR 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Hyperfine, Inc.'s revenue has grown significantly by 807% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
HYPR Growth Metrics (YoY)
HYPR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.4M | -$9.2M | $-0.14 |
| Q2 2025 | $2.7M | -$9.2M | $-0.12 |
| Q1 2025 | $2.1M | -$9.4M | $-0.12 |
| Q3 2024 | $2.3M | -$9.8M | $-0.14 |
| Q2 2024 | $3.4M | -$9.8M | $-0.14 |
| Q1 2024 | $2.6M | -$9.8M | $-0.14 |
| Q3 2023 | $2.3M | -$10.6M | $-0.15 |
| Q2 2023 | $1.5M | -$10.6M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HYPR Capital Allocation
HYPR SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Hyperfine, Inc. (CIK: 0001833769)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HYPR
What is the AI rating for HYPR?
Hyperfine, Inc. (HYPR) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HYPR's key strengths?
Claude: Strong gross margin of 49.8% indicates viable core product economics and unit-level profitability. Fortress balance sheet with $35.1M cash, zero debt, and strong liquidity ratios (4.34x current ratio).
What are the risks of investing in HYPR?
Claude: Severe operating losses of -$37.1M with -273.4% operating margin indicate massive pre-profitability burn unsustainable without revenue acceleration. Operating cash flow of -$27.9M annually against $13.6M revenue demonstrates negative unit economics at operating expense level.
What is HYPR's revenue and growth?
Hyperfine, Inc. reported revenue of $13.6M.
Does HYPR pay dividends?
Hyperfine, Inc. does not currently pay dividends.
Where can I find HYPR SEC filings?
Official SEC filings for Hyperfine, Inc. (CIK: 0001833769) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HYPR's EPS?
Hyperfine, Inc. has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HYPR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Hyperfine, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HYPR stock overvalued or undervalued?
Valuation metrics for HYPR: ROE of -86.8% (sector avg: 15%), net margin of -262.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HYPR stock in 2026?
Our dual AI analysis gives Hyperfine, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HYPR's free cash flow?
Hyperfine, Inc.'s operating cash flow is $-27.9M, with capital expenditures of $1.2M. FCF margin is -214.8%.
How does HYPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -262.3% (avg: 12%), ROE -86.8% (avg: 15%), current ratio 4.34 (avg: 2).